In the H22 tumor‐bearing mouse model, the CSF1/CSF1R inhibitor PLX3397 diminishes macrophage recruitment and M2 polarization and cooperates with immunotherapy by reshaping the tumor immune microenvironment and enhancing infiltration of CD8+T cells and mature DC cells.39 This evidence concerns the gene CD8A and neoplasm.